bioAffinity Showcases CyPath Lung Test at Cleveland Clinic

bioAffinity Technologies, Inc. ( (BIAF) ) has shared an update.

bioAffinity Technologies, Inc., a biotechnology firm specializing in noninvasive lung cancer diagnostics, markets its CyPath® Lung test as a CLIA‑overseen Laboratory Developed Test through its subsidiary Precision Pathology Laboratory Services. The company’s platform uses flow cytometry, artificial intelligence and a fluorescent porphyrin to detect cancer and cancer-related cells in sputum, targeting early-stage lung cancer in high‑risk patients and offering a tool to monitor survivors for recurrence.

On April 7, 2026, bioAffinity Technologies announced that its CyPath® Lung test would be featured at the invitation‑only “Advances in Early Lung Cancer Detection” symposium at the Cleveland Clinic on April 16, 2026, where Chief Medical Officer Gordon Downie, MD, PhD, will join a panel on lung nodule management. The inclusion of CyPath® Lung at this global lung cancer forum underscores the test’s potential operational impact as a noninvasive, cost‑effective adjunct to standard care, promising earlier diagnosis, fewer unnecessary invasive procedures, reduced healthcare costs and stronger industry positioning in the rapidly evolving early detection market.

The most recent analyst rating on (BIAF) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score is held down primarily by weak financial performance (widening losses and accelerating cash burn despite balance sheet repair). Technicals and positive corporate updates around CyPath Lung adoption and studies provide meaningful offset, while valuation remains constrained by ongoing losses and no dividend support.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection, particularly for lung disease. Its lead product, CyPath® Lung, is a sputum-based Laboratory Developed Test that uses flow cytometry and artificial intelligence to identify cancer-related cells with high sensitivity and specificity in high‑risk patients. CyPath® Lung is marketed through Precision Pathology Laboratory Services, a CLIA‑regulated subsidiary targeting early-stage lung cancer detection and ongoing monitoring of lung cancer survivors.

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells, and in clinical studies the assay has demonstrated 92% sensitivity, 87% specificity and 88% accuracy in high‑risk patients with small indeterminate pulmonary nodules, supporting its role in clinical decision‑making.

Average Trading Volume: 8,821,564

Technical Sentiment Signal: Hold

Current Market Cap: $18.8M

See more data about BIAF stock on TipRanks’ Stock Analysis page.